Inovio Pharmaceuticals (INO) vs vTv Therapeutics (VTVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
vTv Therapeutics (VTVT) has outperformed Inovio Pharmaceuticals (INO) over the past year, gaining 36.2% versus a loss of 56.6%. Over five years, VTVT leads with a -47.0% price change compared with -98.6% for INO. vTv Therapeutics is the larger company by market cap ($123.3 million vs $118.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | VTVT |
|---|---|---|
| Share price | $1.15 | $31.18 |
| Market cap | $118.91M | $123.28M |
| 1-day change | +5.50% | +3.66% |
| YTD return | -33.91% | -22.03% |
| 1-year return | -56.60% | +36.22% |
| 5-year return | -98.63% | -46.97% |
| EPS (TTM) | $-0.90 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.72 | $44.00 |
| 52-week low | $0.56 | $19.50 |
| Distance from 52-week high | -57.72% | -29.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +175.65% | +75.47% |
| Average volume | 3.90M | 68.34K |
| Shares outstanding | 103.40M | 3.95M |
| Employees | 112 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTVT has outperformed INO by 92.8 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About vTv Therapeutics
VTVT stock →vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
INO vs VTVT FAQ
Which is bigger, Inovio Pharmaceuticals or vTv Therapeutics?
vTv Therapeutics (VTVT) is larger, with a market capitalization of $123.28M compared with $118.91M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, INO or VTVT?
VTVT returned +36.22% over the past 12 months, compared with -56.60% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and vTv Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.